Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Update: Severe Acute Respiratory Syndrome --- United States, June
11, 2003
CDC continues to work with state and local health departments, the World Health Organization (WHO), and
other partners to investigate cases of severe acute respiratory syndrome (SARS). This report updates SARS cases reported
worldwide and in the United States, and describes the eighth probable U.S. SARS case with laboratory evidence
ofSARS-associated coronavirus (SARS-CoV) infection.
During November 1, 2002--June 11, 2003, a total of 8,435 probable SARS cases were reported to WHO from 29
countries, including 70 from the United States; 789 deaths (case-fatality proportion: 9.4%) have been reported, with no
SARS-related deaths reported from the United States
(1). In the United States, a total of 393 SARS cases have been
reported from 42 states and Puerto Rico, with 323 (82%) cases classified as suspect SARS and 70 (18%) classified as probable SARS (i.e., more
severe illnesses characterized by the presence of pneumonia or acute respiratory distress syndrome)
(2). Of the 70 probable patients, 68 (97%) had traveled to areas with documented or suspected community transmission of SARS within the 10 days before illness onset; the remaining two (3%) patients were a health-care worker who provided care to a SARS patient and
a household contact of a SARS patient (3). Of the 68 probable SARS cases attributed to travel, 35 (51%) patients
reported travel to mainland China; 17 (25%) to Hong Kong Special Administrative Region, China; five (7%) to Singapore; one (1%)
to Hanoi, Vietnam; 14 (21%) to Toronto, Canada; and five (7%) to Taiwan; of these, seven (10%) reported travel to more than one of these areas.
Serologic testing for antibody to SARS-CoV has been completed for 134 suspect and 41 probable cases. None of the
suspect cases and eight (20%) of the probable cases have demonstrated antibodies to SARS-CoV, seven of which have been
described previously (3). The eighth serologically confirmed probable SARS case occurred in a North Carolina resident who traveled to Toronto, Canada, on May 15 and visited a relative in a health-care facility on May 16 and 17. The relative's
hospital roommate and another visitor in the room during these visits both subsequently had SARS diagnosed. The patient returned to
the United States on May 18, and had a fever on May 24, followed by respiratory symptoms. He was treated as an outpatient for these symptoms beginning on May 27, and a chest radiograph on June 3 documented pneumonia. The patient
has remained in isolation at home. All of the exposed health-care workers and family contacts are under active surveillance for SARS.
Serologic testing on this patient was negative for antibody to SARS-CoV at day 10 of illness and positive at day 11. SARS-CoV RNA was not detected by RT-PCR in nasopharyngeal and oropharyngeal swabs collected from the patients 11 days
after onset of symptoms.
Reported by: State and local health departments. SARS Investigative Team, CDC.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
